NCT00909883View on ClinicalTrials.gov

Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)

PHASE3UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2012

Conditions
Parkinson's DiseaseFoot Dystonia
Interventions
DRUG

Botulinum Toxin: Xeomin

45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study

DRUG

Placebo

Placebo injection

Trial Locations (4)

31059

NOT_YET_RECRUITING

CHU Purpan, Toulouse

33600

NOT_YET_RECRUITING

Hôpital Haut-Levêque, Pessac

63003

RECRUITING

CHU Gabriel-Montpied, Clermont-Ferrand

75651

NOT_YET_RECRUITING

Hôpital La Pitié Salpétrière, Paris

Sponsors

Collaborators (1)

Merz Pharmaceuticals
All Listed Sponsors
collaborator

Merz Pharmaceuticals

INDUSTRY

lead

University Hospital, Clermont-Ferrand

OTHER

NCT00909883 - Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Biotech Hunter | Biotech Hunter